A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

NCT05147493 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Renal Impairment
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases

Interventions

DRUG: Isatuximab
DRUG: Bortezomib
DRUG: Cyclophosphamide
DRUG: Dexamethasone
DRUG: Lenalidomide

Sponsor

Hellenic Society of Hematology

Collaborators

[object Object]